Ynsect

Overview of Ynsect

Ynsect was a biotechnology company based in France that focused on producing insect-based protein for use in animal feed, pet food, human consumption, and agricultural fertilizers. Founded in 2011, the company aimed to create a more sustainable protein supply by developing automated insect-rearing technologies. Despite early success and substantial investment, Ynsect filed for bankruptcy in 2025.

History and Founding of Ynsect

Company Origins

Ynsect was established in 2011 in Evry-Courcouronnes, France, by Antoine Hubert, Jean-Gabriel Levon, and others. The company was created to address food sustainability challenges using insects, particularly mealworms (Tenebrio molitor).

Mission and Focus

The company’s mission was to reduce the environmental impact of traditional protein production by using vertically farmed insects. While initially focused on human food, Ynsect pivoted to animal and pet feed due to regulatory and market barriers.

Key Technologies and Achievements

Product Portfolio

Ynsect developed several products, including:

• Sprÿng: Insect protein powder for use in aquaculture, livestock, and pet food.
• Fertilizers: Organic fertilizers derived from insect byproducts.
• Human Ingredients: Expanded into food ingredients through acquisitions such as Protifarm in 2022.

Technological Infrastructure

The company invested heavily in automation, robotics, and computer vision to build large-scale insect-rearing systems. Its facility in Dole, France, was among the largest vertical insect farms globally, housing trillions of mealworms.

Fundraising Milestones

Ynsect raised over $569 million across multiple funding rounds. A $125 million Series C round in 2019 contributed to its unicorn valuation and garnered industry awards for fundraising achievements.

Environmental Goals

The company positioned insect farming as an alternative to resource-intensive protein sources, promoting benefits such as reduced greenhouse gas emissions and land use.

Financial and Operational Challenges

Expansion Costs

Aggressive global expansion and facility development resulted in high capital expenditure. In 2022, the company reported losses of €90 million, with revenue under €600,000.

Market Limitations

Slow regulatory approvals and limited demand for mealworm-based protein in key markets constrained commercial growth. Competition from producers using black soldier flies also affected positioning.

Operational Restructuring

In response to financial pressure, Ynsect closed some operations, including a facility in the Netherlands, and reduced its workforce by 20% in 2023.

Bankruptcy and Reorganization of Ynsect

Filing for Protection

In February 2025, Ynsect filed for judicial reorganization after failing to secure new investment. The company initiated proceedings to transfer some or all assets to new owners.

Factors Contributing to Insolvency

Summary Table: Ynsect

Read the company's most recent news here.